Literature DB >> 12356209

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.

E L J Hoogervorst1, C H Polman, F Barkhof.   

Abstract

OBJECTIVE: Multiple sderosis (MS) patients develop varying degrees of cerebral atrophy, which may already begin at disease onset The purpose of this study is to examine the effect of steroid treatment on cerebral volume in MS patients.
METHODS: Thirty-five MS patients participating in a clinical trial of oral interferon beta, which induded monthly MRI, were included in this study. They suffered from an acute relapse and were treated with intravenous methylprednisolone (IV-MP); 13 of the patients were treated with oral prednisolone tapering after IV-MP. The last MRI scan before and the first (and second for oral tapering patients) scan after IV-MP treatment were used for measuring parenchymal fraction (PF) and ventricular fraction (VF). Changes in PF and VF were analysed using Student's t test.
RESULTS: For the total population no significant changes in PF or VF were found. However, the subgroup of patients receiving oral tapering after IV-MP showed changes, compatible with atrophy in both PF and VF, that were significant immediately after IV-MP treatment and still persisted (though not statistically significant anymore) after a mean interval of 30 days. The magnitude of these changes was about the same as the annual change in cerebral volume as reported in natural history studies.
CONCLUSION: Our data indicate that short courses of intravenous steroids (restricted to three or five days) have no major impact, whereas prolonged treatment with oral tapering does significantly affect brain volume. These findings are important for longitudinal studies and clinical trials in which brain volume is used as an outcome measure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356209     DOI: 10.1191/1352458502ms838oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 2.  Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Authors:  Ludwig Kappos; Jens Kuhle; Achim Gass; Lutz Achtnichts; Ernst-Wilhelm Radue
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Authors:  Pietro Annovazzi; Valentina Tomassini; Benedetta Bodini; Laura Boffa; Massimiliano Calabrese; Eleonora Cocco; Cinzia Cordioli; Giovanna De Luca; Giovanni Frisullo; Antonio Gallo; Simona Malucchi; Damiano Paolicelli; Ilaria Pesci; Marta Radaelli; Paolo Ragonese; Luca Roccatagliata; Carla Tortorella; Marco Vercellino; Valentina Zipoli; Claudio Gasperini; Mariaemma Rodegher; Claudio Solaro
Journal:  Neurol Sci       Date:  2012-03-11       Impact factor: 3.307

4.  Concentration dependent actions of glucocorticoids on neuronal viability and survival.

Authors:  István M Abrahám; Peter Meerlo; Paul G M Luiten
Journal:  Dose Response       Date:  2006-06-20       Impact factor: 2.658

5.  Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.

Authors:  F Durand-Dubief; B Belaroussi; J P Armspach; M Dufour; S Roggerone; S Vukusic; S Hannoun; D Sappey-Marinier; C Confavreux; F Cotton
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

6.  The effect of corticosteroid medication on quantitative MR parameters of the brain.

Authors:  Stefan C A Steens; Gerda M Steup-Beekman; Gerlof P Th Bosma; Faiza Admiraal-Behloul; Hans Olofsen; Joost Doornbos; Tom W J Huizinga; Mark A van Buchem
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

7.  Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.

Authors:  Magí Andorra; Kunio Nakamura; Erika J Lampert; Irene Pulido-Valdeolivas; Irati Zubizarreta; Sara Llufriu; Eloy Martinez-Heras; Nuria Sola-Valls; María Sepulveda; Ana Tercero-Uribe; Yolanda Blanco; Albert Saiz; Pablo Villoslada; Elena H Martinez-Lapiscina
Journal:  JAMA Neurol       Date:  2018-10-01       Impact factor: 18.302

Review 8.  Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.

Authors:  Elliot M Frohman; Anjali Shah; Eric Eggenberger; Luanne Metz; Robert Zivadinov; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

9.  Measuring brain volume by MR imaging: impact of measurement precision and natural variation on sample size requirements.

Authors:  R G Steen; R M Hamer; J A Lieberman
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

10.  Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.

Authors:  P Svolos; W E Reddick; A Edwards; A Sykes; Y Li; J O Glass; Z Patay
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.